Cargando…

Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates

Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on th...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Andrew D., Tran, Andy C., Sibley, Laura, Sarfas, Charlotte, Morrison, Alexandra L., Lawrence, Steve, Dennis, Mike, Clark, Simon, Zadi, Sirine, Lanni, Faye, Rayner, Emma, Copland, Alastair, Hart, Peter, Diogo, Gil Reynolds, Paul, Matthew J., Kim, Miyoung, Gleeson, Fergus, Salguero, Francisco J., Singh, Mahavir, Stehr, Matthias, Cutting, Simon M., Basile, Juan I., Rottenberg, Martin E., Williams, Ann, Sharpe, Sally A., Reljic, Rajko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594996/
https://www.ncbi.nlm.nih.gov/pubmed/37881438
http://dx.doi.org/10.3389/fimmu.2023.1246826
_version_ 1785124769417396224
author White, Andrew D.
Tran, Andy C.
Sibley, Laura
Sarfas, Charlotte
Morrison, Alexandra L.
Lawrence, Steve
Dennis, Mike
Clark, Simon
Zadi, Sirine
Lanni, Faye
Rayner, Emma
Copland, Alastair
Hart, Peter
Diogo, Gil Reynolds
Paul, Matthew J.
Kim, Miyoung
Gleeson, Fergus
Salguero, Francisco J.
Singh, Mahavir
Stehr, Matthias
Cutting, Simon M.
Basile, Juan I.
Rottenberg, Martin E.
Williams, Ann
Sharpe, Sally A.
Reljic, Rajko
author_facet White, Andrew D.
Tran, Andy C.
Sibley, Laura
Sarfas, Charlotte
Morrison, Alexandra L.
Lawrence, Steve
Dennis, Mike
Clark, Simon
Zadi, Sirine
Lanni, Faye
Rayner, Emma
Copland, Alastair
Hart, Peter
Diogo, Gil Reynolds
Paul, Matthew J.
Kim, Miyoung
Gleeson, Fergus
Salguero, Francisco J.
Singh, Mahavir
Stehr, Matthias
Cutting, Simon M.
Basile, Juan I.
Rottenberg, Martin E.
Williams, Ann
Sharpe, Sally A.
Reljic, Rajko
author_sort White, Andrew D.
collection PubMed
description Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on the surface of inactivated Bacillus subtilis spores. The candidate conferred significant protection against Mycobacterium. tuberculosis challenge in naïve guinea pigs and markedly improved protection in the lungs and spleens of animals primed with BCG. We then immunized rhesus macaques with BCG intradermally, and subsequently boosted with one intradermal and one aerosol dose of Spore-FP1, prior to challenge with low dose aerosolized M. tuberculosis Erdman strain. Following vaccination, animals did not show any adverse reactions and displayed higher antigen specific cellular and antibody immune responses compared to BCG alone but this did not translate into significant improvement in disease pathology or bacterial burden in the organs.
format Online
Article
Text
id pubmed-10594996
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105949962023-10-25 Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates White, Andrew D. Tran, Andy C. Sibley, Laura Sarfas, Charlotte Morrison, Alexandra L. Lawrence, Steve Dennis, Mike Clark, Simon Zadi, Sirine Lanni, Faye Rayner, Emma Copland, Alastair Hart, Peter Diogo, Gil Reynolds Paul, Matthew J. Kim, Miyoung Gleeson, Fergus Salguero, Francisco J. Singh, Mahavir Stehr, Matthias Cutting, Simon M. Basile, Juan I. Rottenberg, Martin E. Williams, Ann Sharpe, Sally A. Reljic, Rajko Front Immunol Immunology Tuberculosis remains a major health threat globally and a more effective vaccine than the current Bacillus Calmette Guerin (BCG) is required, either to replace or boost it. The Spore-FP1 mucosal vaccine candidate is based on the fusion protein of Ag85B-Acr-HBHA/heparin-binding domain, adsorbed on the surface of inactivated Bacillus subtilis spores. The candidate conferred significant protection against Mycobacterium. tuberculosis challenge in naïve guinea pigs and markedly improved protection in the lungs and spleens of animals primed with BCG. We then immunized rhesus macaques with BCG intradermally, and subsequently boosted with one intradermal and one aerosol dose of Spore-FP1, prior to challenge with low dose aerosolized M. tuberculosis Erdman strain. Following vaccination, animals did not show any adverse reactions and displayed higher antigen specific cellular and antibody immune responses compared to BCG alone but this did not translate into significant improvement in disease pathology or bacterial burden in the organs. Frontiers Media S.A. 2023-10-10 /pmc/articles/PMC10594996/ /pubmed/37881438 http://dx.doi.org/10.3389/fimmu.2023.1246826 Text en Copyright © 2023 White, Tran, Sibley, Sarfas, Morrison, Lawrence, Dennis, Clark, Zadi, Lanni, Rayner, Copland, Hart, Diogo, Paul, Kim, Gleeson, Salguero, Singh, Stehr, Cutting, Basile, Rottenberg, Williams, Sharpe and Reljic https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
White, Andrew D.
Tran, Andy C.
Sibley, Laura
Sarfas, Charlotte
Morrison, Alexandra L.
Lawrence, Steve
Dennis, Mike
Clark, Simon
Zadi, Sirine
Lanni, Faye
Rayner, Emma
Copland, Alastair
Hart, Peter
Diogo, Gil Reynolds
Paul, Matthew J.
Kim, Miyoung
Gleeson, Fergus
Salguero, Francisco J.
Singh, Mahavir
Stehr, Matthias
Cutting, Simon M.
Basile, Juan I.
Rottenberg, Martin E.
Williams, Ann
Sharpe, Sally A.
Reljic, Rajko
Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title_full Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title_fullStr Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title_full_unstemmed Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title_short Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
title_sort spore-fp1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on bcg-conferred protection in non-human primates
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594996/
https://www.ncbi.nlm.nih.gov/pubmed/37881438
http://dx.doi.org/10.3389/fimmu.2023.1246826
work_keys_str_mv AT whiteandrewd sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT tranandyc sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT sibleylaura sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT sarfascharlotte sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT morrisonalexandral sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT lawrencesteve sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT dennismike sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT clarksimon sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT zadisirine sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT lannifaye sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT rayneremma sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT coplandalastair sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT hartpeter sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT diogogilreynolds sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT paulmatthewj sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT kimmiyoung sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT gleesonfergus sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT salguerofranciscoj sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT singhmahavir sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT stehrmatthias sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT cuttingsimonm sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT basilejuani sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT rottenbergmartine sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT williamsann sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT sharpesallya sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates
AT reljicrajko sporefp1tuberculosismucosalvaccinecandidateishighlyprotectiveinguineapigsbutfailstoimproveonbcgconferredprotectioninnonhumanprimates